Early Bronchodilating Effect of a New Oral Beta-2-Receptor Agonist (Broxaterol) in Bronchial Asthma

Chetta, Alfredo; Garavaldi, G.; Cuomo, Angelo; Gurrieri, G; Olivieri, Dario

doi:10.1159/000195423

Cited by 4 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The onset of action of broxaterol was seen at 30 min, which was more rapid than for procaterol. Peak effect was reached at 120 min for both drugs, and an unusual persistence of bronchodilation, when compared to placebo, lasted up to 8 h. No study has shown a longer-lasting effect of oral broxaterol than that reported by Chetta et al [7].…”

Section: Oral Tablet Studiesmentioning

confidence: 66%

“…Minette and Prihadi [13] reported an increase in heart rate of 4-8 beats/min and in systolic blood pressure of up to 10 mm Hg lasting several hours. These effects were greater than those produced by salbutamol 4 mg. Chetta et al [7] reported a slight increase in heart rate 30-120 min after both broxa terol and procaterol.…”

Section: Cardiovascular Effectsmentioning

confidence: 97%

“…Chetta et al [7] compared oral broxa terol 0.5 mg with procaterol 0.05 mg in a double-blind cross-over study in 12 pa tients. The onset of action of broxaterol was seen at 30 min, which was more rapid than for procaterol.…”

Section: Oral Tablet Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Broxaterol: Therapeutic Trials and Safety Profile

Ziment

1989

Respiration

View full text Add to dashboard Cite

The efficacy and the safety profile of broxaterol have been assessed in multicenter open studies and in some double-blind controlled clinical trials. Broxaterol (0.6–1.2 mg/day by metered dose inhaler or 0.5–1.5 mg/day orally, from 2 weeks to 1 year) produced a significant clinical improvement, an increase in FEV₁ and a decrease in supplemental anti-asthmatic drugs used in patients with reversible airflow obstruction and in asthmatic children. The increases in FEV₁ versus baseline were significantly maintained after the end of the treatment. Prompt disappearance of the asthmatic attack with significant improvement in lung function was observed in children. In two long-term controlled trials the respiratory effects of broxaterol nebulizer solution were significantly greater than placebo. Moreover, broxaterol by metered dose inhaler was more effective than salbutamol after 3 months follow-up, showing absence of tachyphylaxis. In long-term clinical evaluation, broxaterol has been shown to be well tolerated, with an incidence of adverse reactions equal to or less than that reported in the literature for other β₂-agonists. The side effects most frequently associated with broxaterol were tremor, nervousness and palpitations. They usually appeared to be slight, transient and dose-related, requiring withdrawal from clinical trials in only 12 patients out of 274 (4.4%). Clinically relevant changes in heart rate and blood pressure were never reported. Broxaterol was found not to modify the ECG or haematological, hepatic and renal laboratory tests. No metabolic abnormalities or hypokalemia were caused by long-term treatment with broxaterol.

show abstract

Section: Oral Tablet Studiesmentioning

confidence: 66%

Section: Cardiovascular Effectsmentioning

confidence: 97%